Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care. by Binder, Adam F et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Medical Oncology Faculty 
Papers Department of Medical Oncology 
1-1-2020 
Treating Hematologic Malignancies During a Pandemic: Utilizing 
Telehealth and Digital Technology to Optimize Care. 
Adam F Binder 
Thomas Jefferson University 
Nathan R Handley 
Thomas Jefferson University 
Lindsay Wilde 
Thomas Jefferson University 
Neil Palmisiano 
Thomas Jefferson University 
Ana Maria Lopez 
Thomas Jefferson University 
Follow this and additional works at: https://jdc.jefferson.edu/medoncfp 
 Part of the Oncology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Binder, Adam F; Handley, Nathan R; Wilde, Lindsay; Palmisiano, Neil; and Lopez, Ana Maria, 
"Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital 
Technology to Optimize Care." (2020). Department of Medical Oncology Faculty Papers. Paper 
118. 
https://jdc.jefferson.edu/medoncfp/118 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
PERSPECTIVE
published: 26 June 2020
doi: 10.3389/fonc.2020.01183
Frontiers in Oncology | www.frontiersin.org 1 June 2020 | Volume 10 | Article 1183
Edited by:
Alessandro Isidori,
AORMN Hospital, Italy
Reviewed by:
Alice Mims,
The Ohio State University,
United States
Michele Malagola,
University of Brescia, Italy
*Correspondence:
Adam F. Binder
adam.binder@jefferson.edu
Specialty section:
This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology
Received: 14 May 2020
Accepted: 11 June 2020
Published: 26 June 2020
Citation:
Binder AF, Handley NR, Wilde L,
Palmisiano N and Lopez AM (2020)
Treating Hematologic Malignancies
During a Pandemic: Utilizing
Telehealth and Digital Technology to
Optimize Care. Front. Oncol. 10:1183.
doi: 10.3389/fonc.2020.01183
Treating Hematologic Malignancies
During a Pandemic: Utilizing
Telehealth and Digital Technology to
Optimize Care
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Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA,
United States
In late January 2020, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2)
was reported as an outbreak in Wuhan, China. Within 2 months it became a global
pandemic. Patients with cancer are at highest risk for both contracting and suffering
complications of its resultant disease, Coronavirus 19 (COVID-19). Healthcare systems
across the world had to adapt quickly to mitigate this risk, while continuing to provide
potentially lifesaving treatment to patients. Bringing care to the home through the use of
telehealth, home based chemotherapy, and remote patient monitoring technologies can
help minimize risk to the patient and healthcare workers without sacrificing quality of care
delivered. These care models provide the right treatment, to the right patient, at the right
time, in the right place. Whether these patient-centered models of care will continue to
be embraced by key stakeholders after the pandemic remains uncertain.
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INTRODUCTION
In late January 2020, the outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS
CoV-2) and its resultant disease, Coronavirus 19 (COVID-19), was reported as an emerging
epidemic in Wuhan, China. Within 2 months, COVID-19 became a global pandemic (1).
Individuals at highest risk for severe complications tend to be older (>65 years old) with multiple
comorbidities (2). Patients with hematologic malignancies fall into this category; these patients
have a median age of diagnosis of 70.6 years (3) and many are immunosuppressed due to either the
cancer itself or to the treatment regimen they are receiving. Patients with hematologic malignancies
are at even high risk for infection as a result of immune dysregulation that can persist even
years after treatment is completed (4). In addition, patients with hematologic malignancies have
frequent contact with the health care system, increasing their risk for exposure and infection
(5). As a result of increased susceptibility and contact with the healthcare system, patients with
hematologic malignancies appear to have a higher incidence of COVID-19 infection and severe
complications (6–8).
In order to minimize risk to the population at large, governments have implemented mitigation
policies that include mandatory shelter in place orders and social distancing rules. These measures
have challenged cancer centers to develop strategies to continue to provide appropriate care while
minimizing risk of infection for both patients and healthcare teams. These strategies include
workflow processes to create an environment to allow for social distancing; operational models
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to ensure access to appropriate screening, testing, and
personal protective equipment; treatment modifications,
such as personalizing timing of cancer treatment based on
emerging national and international guidelines and the specific
characteristics of the patient’s disease, underlying morbidities,
and risk; and care decentralization, enabling patients to shelter
in place while continuing to receive the care they need (9).
Decentralized care—bringing care to the patient, rather than
the traditional approach of bringing the patient to care—
takes advantage of the growing capabilities of health systems
and their patients to utilize telecommunications technology to
enable health care delivery to the patient. Tools for enabling
decentralized care include (10) telehealth visits, home based
care, and remote patient monitoring. Herein, we will examine
the benefits, barriers and considerations for each of these
components of decentralized care with a focus on how they
are important in providing appropriate care during the current
pandemic and how they can become integrated into standard of
care in the future.
Telehealth Visits
Telehealth visits (clinician-patient visits using two-way, real-time
audiovisual or audio-only technology, or physician-physician
synchronous or asynchronous consultations) can minimize
healthcare exposure. These visits can be utilized for new or
routine follow-up of patients with hematologic malignancies
(11). Telehealth visits not only protect patients from exposure
risk, but also mitigate exposure for the healthcare teams.
According to a CDC report, as of April 15th, 2020, of the
healthcare professionals who have contracted COVID-19 in the
United States, about 55% of those cases were thought to be due
to work-related exposures (12). Ensuring that providers are only
seeing patients when it will truly change management decisions
may reduce transmission of SARS-CoV-2.
Outpatient
While telehealth visits have been utilized for decades prior to the
pandemic (13, 14), their use has dramatically increased following
the onset of COVID-19 (10). At Sidney Kimmel Cancer Center at
Thomas Jefferson University, the use of telehealth increased from
<2.0 to over 50% of all hematologic malignancy visits within
weeks. This rapid scale was possible as a result of an existing
robust telehealth program within the Jefferson Health enterprise.
In audiovisual visits, one can perform almost all aspects of an in-
person visit. Physical exams are dynamic. If the patient is alone,
exam may be limited to observational only. If the patient has a
caregiver with them, one can observe patient response to certain
manipulations of joints or palpation of specific areas. With the
right digital tools, such as remote patient monitoring devices to
obtain vital signs as well as a digital stethoscope to auscultate
the heart and lungs, along with a caregiver to perform certain
palpation techniques, one can complete a thorough physical
exam (15). These visits can be used for routine follow-up (16)
or acute care (17) with an overall positive patient experience.
Unpublished post-visit survey data (completed within 2 weeks
of the telehealth visit) from our institution revealed that for all
patients with cancer, 99% of patients were satisfied with their
telehealth visit; 91% of patients agreed our telehealth visit system
(JeffConnect) was easy to use; 94% said they would use telehealth
visits again; 87% felt it provided the same care as an in person
visit; on a 10-point scale, average likelihood to recommend
JeffConnect to a friend or colleague was 9.16 (net promoter score
68, n= 97).
To further promote the use of telehealth visits, the Center
for Medicare and Medicaid Services (CMS) has liberalized
reimbursement regulations for telehealth services during the
pandemic (18). Previously, CMS reimbursements for telehealth
visits were restricted to those over the age of 65 and who lived in
rural communities. In addition, these visits had to take place in a
rural health care facility and only within an established patient-
physician relationship. Now, telehealth visits can occur from any
location for either new or follow-up clinic visits. Both audio-
visual and audio-only telehealth visits are now reimbursed on
par with a face-to-face visit. Transitioning patients to telehealth
visits, particularly those on oral chemotherapy or post-treatment
follow up, can reduce an individual patient’s risk for exposure,
while at the same time minimizing exposure risk for the clinician
and preserving personal protective equipment (PPE) (9).
Inpatient
Inpatient teleconsultations were initiated at our institution via a
telehealth HIPAA-compliant system that allows consulting teams
to perform audiovisual telehealth visits in the hospital in order
to minimize exposure to patients and staff. While this model is
well-established for tele-psychiatry (19), intensive care (20), and
pediatrics (21) it is increasingly used in cancer care (15). Patients
with COVID-19 can continue to receive subspecialty care
without healthcare workers exposing themselves unnecessarily.
In addition, at a time when patients’ families are not allowed in
the hospital, and patients in the hospital feel increasingly isolated,
it provides an opportunity for family members and caregivers to
simultaneously connect with healthcare workers and the patient
in order to continue to be involved in healthcare decisionmaking.
Physician-Physician
Physician to physician directed synchronous and asynchronous
models enable information exchange between clinicians without
physical contact (22–26). It also often reduces the number of
patient-physician encounters. In the outpatient setting at the
VA, use of asynchronous hematology e-consultative services
reduced the number of face-to-face referrals (27). In hematologic
malignancies, asynchronous e-consultation may be particularly
useful in reducing referrals and patient evaluations for diseases,
such as early stage CLL, asymptomatic indolent lymphomas,
myeloproliferative neoplasms, or plasma cell dyscrasias, where
the initial work up can be completed by the referring physician
and active surveillance is often the recommended standard of
care approach.
For patients with newly diagnosed hematologic malignancies,
timely evaluation and treatment is central to optimizing
outcomes. With new CMS regulations allowing for initial
evaluation via telehealth visits, patients can complete their initial
visit via telehealth, while in-person visits can be reserved for
those who are acutely symptomatic or in need of diagnostic
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interventions such as a bone marrow biopsy or lumbar puncture.
For those who establish care via a telehealth visit and need to
initiate treatment, tele-consenting models may facilitate starting
therapy (28). Initial data suggest that patients are satisfied with
tele-consenting (29).
Implementation of these programs is not without challenges.
Lack of reliable internet access, lack of education on how
to use smart devices, and lack of a smart device are major
barriers to widespread implementation of telehealth. A previous
study revealed that those, who are older, are of minority race
or ethnicity or with less than a college education are less
likely to have access to home internet (30). With the right
support, however, these limitationsmay be overcome. At Thomas
Jefferson University, in response to COVID-19, a telehealth task
force was implemented. This group has worked diligently to
ensure every patient has the capabilities to complete a video visit.
This support ranges from taking patients through a step by step
process for setting up the patient portal to providing a free tablet
computer to complete the necessary visits. While these efforts
require significant resources, they have been coupled by a rise
in the percentage of patients who have been able to successfully
complete a video visit.
While telehealth strategies are an effective way of establishing
care and initiating treatment during the current pandemic, they
may prove to be important components of standard of care in
the future. Additional research into the impact of telemedicine
on the patient-physician relationship, time to treatment, cost of
care, patient and clinician satisfaction, and outcomes is needed.
HOME BASED THERAPY
Home based therapy is the treatment of patients in the home
setting either with anti-neoplastic agents or supportive therapies.
For some patients with hematologic malignancies, such as acute
leukemia or high-grade B cell lymphomas, treatment cannot be
safely postponed and carries significant nosocomial infection
risks by way of exposure to carriers (many of whom may be
asymptomatic) (31). Home based chemotherapy can mitigate
this risk.
While not well-established in the US, models for the delivery
of home chemotherapy exist globally and have been shown
to be safe, patient centered, and more cost effective when
compared to the hospital or infusion center (32–35). However,
home chemotherapy comes with unique challenges. For instance,
to care for the same number of patients, significant staffing
changes must occur, as nurses must travel from one home to
the next as opposed to simultaneously caring for patients in
adjacent infusion chairs. Other logistical challenges exist. USP-
800 regulations must be followed for compounding, storing,
administering and disposing of chemotherapeutic agents (36)
and drug stability must be considered so medications are
delivered and administered in the appropriate time frame.
Tracking of home chemotherapy administration in the electronic
medical record must also be completed accurately, reliably,
and in a timely fashion. However, creative solutions for these
problems can be developed. For example, for some agents, such
as injectable medications (i.e., bortezomib, rituximab-hycela), a
telehealth infusion model could exist in which a chemotherapy
certified nurse observes self-administration and proper disposal
via a telehealth visit.
In addition to chemotherapy administration, home blood
product transfusion can also be implemented to minimize
exposure to the healthcare system. Some patients with
myelodysplastic syndrome or acute leukemia require frequent,
often biweekly, transfusions and are concurrently neutropenic,
greatly increasing their risk for infection. Home-based blood
transfusion programs are uncommon in the US but are more
widely implemented in Europe and are safe, effective, and
preferred by patients (37–39). If more broadly implemented,
patients with hematologic malignancies would benefit greatly
from ongoing programs that are able to provide these therapies
at home. The current COVID-19 pandemic may be the catalyst
for change that has been needed to allow for these services to
become standard of care.
Remote Patient Monitoring
Remote patient monitoring (RPM) is the use of web-based
systems and wearable sensors to monitor health data.
Utilization of these digital technologies during the pandemic
can allow clinical teams to closely monitor patients with
hematologic malignancies.
For patients with advanced cancer who are receiving
chemotherapy, monitoring symptoms via electronic patient
reported outcomes (ePROs) has been shown to improve
symptom management, decrease acute care utilization, and
improve overall survival (40–42). Reducing acute care utilization
is particularly important during the COVID-19 pandemic as
acute care resources may become scarce and resource allocation
may become challenging. Ongoing studies are evaluating the
applicability of ePROs in hematologic malignancies (43). While
initial results are promising, implementation can be challenging
and requires expertise (44). Digital health literacy varies based
on age and education level (30) and understanding a practice’s
patient population is important when considering the various
models for ePRO implementation.
In addition to monitoring patient’s reported symptoms,
continuous biometric data monitoring in combination
with standard interventions has shown some promise in
supplementing home based care, though results have been mixed
to date (45–49). Most studies have evaluated integration of
activity trackers or continuous temperature monitoring into
patient care. Activity trackers have been studied to assess effects
of treatment; baseline activity prior to treatment has been
shown to be prognostic (48–50). With respect to temperature
monitoring, a pilot study demonstrated that inpatient continuous
temperature monitoring in neutropenic patients identified fever
11.4 h earlier than routine intermittent temperature monitoring
(51). Multiple RPM studies are ongoing1,2. While there is
1ClinicalTrials.gov. Available online at: https://clinicaltrials.gov/ct2/results?cond=
remote$+$patient$+$monitoring&term=oncology&cntry=&state=&city=&dist=
(accessed June 1, 2020).
2ClinicalTrials.gov. Remote Outpatient Temperature Monitoring for Early
Detection of Febrile Neutropenia After Chemotherapy (REMEDY). Available online
at: https://clinicaltrials.gov/ct2/show/NCT04081753 (accessed June 1, 2020).
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significant promise in the field of RPM, many questions
regarding its use remain, and how it will apply to patient with
hematologic malignancies is unclear. The COVID-19 pandemic
may highlight the potential utility of RPM and accelerate
research in this area.
CONCLUSION
The COVID-19 pandemic has rapidly changed care delivery.
The swift adoption of decentralization strategies like telehealth
visits, home-based care, and remote patient monitoring can allow
physicians treating hematologic malignancies to maintain care
while mitigating the risk of nosocomial SARS-COV-2 infection.
These tools can be utilized across the spectrum of care from,
prevention (26) to palliation (52), to reduce the care burden as
well as decrease exposure risk for patients and health care teams.
Decentralization of care can provide a patient-centered approach
that follows a precision medicine algorithm with an extra feature:
providing the right treatment, to the right patient, at the right
time and in the right place. Whether these strategies will continue
to be wholeheartedly embraced by key stakeholders—health care
professionals, patients, and payers—as the pandemic subsides
remains to be seen.
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